UBS Group
CRSP icon

UBS Group’s CRISPR Therapeutics CRSP Stock Holding History

UBS Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.9M Sell
1,317,499
-445,031
-25% -$23.5M 0.01% 1394
2026
Q1 		$83.8M Sell
1,762,530
-761,614
-30% -$40.2M 0.01% 1191
2025
Q4 		$132M Buy
2,524,144
+185,088
+8% +$11.1M 0.02% 817
2025
Q3 		$152M Sell
2,339,056
-504,521
-18% -$29M 0.02% 742
2025
Q2 		$138M Buy
2,843,577
+771,685
+37% +$29.9M 0.02% 746
2025
Q1 		$70.5M Buy
2,071,892
+87,902
+4% +$3.73M 0.01% 1171
2024
Q4 		$78.1M Buy
1,983,990
+1,310,402
+195% +$61.9M 0.01% 1082
2024
Q3 		$31.6M Buy
673,588
+249,372
+59% +$12.7M 0.01% 1481
2024
Q2 		$22.9M Buy
424,216
+103,839
+32% +$6.01M 0.01% 1578
2024
Q1 		$21.8M Buy
320,377
+9,472
+3% +$678K 0.01% 1620
2023
Q4 		$19.5M Sell
310,905
-26,225
-8% -$1.45M 0.01% 1603
2023
Q3 		$15.3M Buy
337,130
+74,470
+28% +$3.85M 0.01% 1674
2023
Q2 		$14.7M Buy
262,660
+17,807
+7% +$1.01M 0.01% 1682
2023
Q1 		$11.1M Sell
244,853
-203,682
-45% -$9.89M ﹤0.01% 1813
2022
Q4 		$18.2M Buy
448,535
+180,573
+67% +$9.58M 0.01% 1479
2022
Q3 		$17.5M Buy
267,962
+34,043
+15% +$2.47M 0.01% 1369
2022
Q2 		$14.2M Buy
233,919
+30,487
+15% +$1.79M 0.01% 1567
2022
Q1 		$12.8M Buy
203,432
+13,542
+7% +$850K ﹤0.01% 1750
2021
Q4 		$14.4M Buy
189,890
+50,237
+36% +$4.39M ﹤0.01% 1827
2021
Q3 		$15.6M Buy
139,653
+23,879
+21% +$3M ﹤0.01% 1691
2021
Q2 		$18.7M Sell
115,774
-122,105
-51% -$14.9M 0.01% 1536
2021
Q1 		$29M Buy
237,879
+102,618
+76% +$15.5M 0.01% 1179
2020
Q4 		$20.7M Buy
135,261
+42,068
+45% +$4.97M 0.01% 1325
2020
Q3 		$7.79M Buy
93,193
+8,799
+10% +$781K ﹤0.01% 1831
2020
Q2 		$6.2M Buy
84,394
+15,848
+23% +$927K ﹤0.01% 1879
2020
Q1 		$2.91M Buy
68,546
+12,153
+22% +$628K ﹤0.01% 2401
2019
Q4 		$3.44M Buy
56,393
+10,936
+24% +$597K ﹤0.01% 2976
2019
Q3 		$1.86M Sell
45,457
-11,507
-20% -$550K ﹤0.01% 3353
2019
Q2 		$2.68M Buy
56,964
+570
+1% +$22.8K ﹤0.01% 2885
2019
Q1 		$2.02M Buy
56,394
+5,400
+11% +$187K ﹤0.01% 2988
2018
Q4 		$1.46M Sell
50,994
-30,560
-37% -$1.06M ﹤0.01% 3345
2018
Q3 		$3.62M Sell
81,554
-971
-1% -$50.9K ﹤0.01% 2654
2018
Q2 		$4.85M Buy
82,525
+23,130
+39% +$1.32M ﹤0.01% 2365
2018
Q1 		$2.71M Buy
59,395
+57,025
+2,406% +$2.35M ﹤0.01% 2868
2017
Q4 		$56K Buy
2,370
+1,800
+316% +$34.2K ﹤0.01% 5743
2017
Q3 		$10K Sell
570
-958
-63% -$17.4K ﹤0.01% 6883
2017
Q2 		$25K Buy
1,528
+958
+168% +$15.8K ﹤0.01% 6135
2017
Q1 		$12K Sell
570
-3,472
-86% -$68.2K ﹤0.01% 6500
2016
Q4 		$82K Buy
+4,042
New +$75.5K ﹤0.01% 5433

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group's CRSP Position: Q2 2026 in Review

UBS Group reduced its CRISPR Therapeutics (CRSP) stake by 25% in Q2 2026, selling an estimated $23.5M and leaving 1,317,499 shares worth $71.9M. The position accounts for 0.01% of the portfolio, ranked #1394.

UBS Group first reported a position in CRSP in Q4 2016 and has held it in 39 quarters since. The position peaked at $152M in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • UBS Group held 1,317,499 shares of CRISPR Therapeutics worth $71.9M as of Q2 2026.
  • UBS Group sold 445,031 CRISPR Therapeutics shares in Q2 2026, an estimated $23.5M.
  • CRISPR Therapeutics made up 0.01% of UBS Group's portfolio in Q2 2026, its #1394 holding.
  • UBS Group first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 39 quarters since.
  • UBS Group's CRISPR Therapeutics position peaked at $152M in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.